These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
606 related articles for article (PubMed ID: 31703838)
1. NLRP3 inflammasome negatively regulates podocyte autophagy in diabetic nephropathy. Hou Y; Lin S; Qiu J; Sun W; Dong M; Xiang Y; Wang L; Du P Biochem Biophys Res Commun; 2020 Jan; 521(3):791-798. PubMed ID: 31703838 [TBL] [Abstract][Full Text] [Related]
2. Artificially Cultivated Wang C; Hou XX; Rui HL; Li LJ; Zhao J; Yang M; Sun LJ; Dong HR; Cheng H; Chen YP J Diabetes Res; 2018; 2018():1390418. PubMed ID: 30534570 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y Metabolism; 2021 May; 118():154748. PubMed ID: 33675822 [TBL] [Abstract][Full Text] [Related]
4. Spop ameliorates diabetic nephropathy through restraining NLRP3 inflammasome. Wang B; Dai Z; Gao Q; Liu Y; Gu G; Zheng H Biochem Biophys Res Commun; 2022 Feb; 594():131-138. PubMed ID: 35081502 [TBL] [Abstract][Full Text] [Related]
5. [Triptolide inhibits NLRP3 inflammasome activation and ameliorates podocyte epithelial-mesenchymal transition induced by high glucose]. Wu W; Liu BH; Wan YG; Sun W; Liu YL; Wang WW; Fang QJ; Tu Y; Yee HY; Yuan CC; Wan ZY Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(24):5457-5464. PubMed ID: 32237395 [TBL] [Abstract][Full Text] [Related]
6. Purinergic 2X7 Receptor is Involved in the Podocyte Damage of Obesity-Related Glomerulopathy via Activating Nucleotide-Binding and Oligomerization Domain-Like Receptor Protein 3 Inflammasome. Hou XX; Dong HR; Sun LJ; Yang M; Cheng H; Chen YP Chin Med J (Engl); 2018 Nov; 131(22):2713-2725. PubMed ID: 30425198 [TBL] [Abstract][Full Text] [Related]
7. Podocyte-specific silencing of acid sphingomyelinase gene to abrogate hyperhomocysteinemia-induced NLRP3 inflammasome activation and glomerular inflammation. Huang D; Kidd JM; Zou Y; Wu X; Li N; Gehr TWB; Li PL; Li G Am J Physiol Renal Physiol; 2024 Jun; 326(6):F988-F1003. PubMed ID: 38634138 [TBL] [Abstract][Full Text] [Related]
8. Rac1 GTPase Inhibition Blocked Podocyte Injury and Glomerular Sclerosis during Hyperhomocysteinemia via Suppression of Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation. Zhang Q; Conley SM; Li G; Yuan X; Li PL Kidney Blood Press Res; 2019; 44(4):513-532. PubMed ID: 31266025 [TBL] [Abstract][Full Text] [Related]
9. Luteolin attenuates high glucose-induced podocyte injury via suppressing NLRP3 inflammasome pathway. Yu Q; Zhang M; Qian L; Wen D; Wu G Life Sci; 2019 May; 225():1-7. PubMed ID: 30935950 [TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2. Kim D; Ban KY; Lee GH; Jun HS Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373116 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-10 negatively regulates inflammation in diabetic kidney via targeting activation of the NLRP3 inflammasome. Ding H; Li J; Li Y; Yang M; Nie S; Zhou M; Zhou Z; Yang X; Liu Y; Hou FF Mol Ther; 2021 Jul; 29(7):2308-2320. PubMed ID: 33744467 [TBL] [Abstract][Full Text] [Related]
12. Optineurin inhibits NLRP3 inflammasome activation by enhancing mitophagy of renal tubular cells in diabetic nephropathy. Chen K; Feng L; Hu W; Chen J; Wang X; Wang L; He Y FASEB J; 2019 Mar; 33(3):4571-4585. PubMed ID: 30571313 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation. Wang S; Li Y; Fan J; Zhang X; Luan J; Bian Q; Ding T; Wang Y; Wang Z; Song P; Cui D; Mei X; Ju D Cell Death Dis; 2017 Jul; 8(7):e2937. PubMed ID: 28726774 [TBL] [Abstract][Full Text] [Related]
14. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. Bai M; Chen Y; Zhao M; Zhang Y; He JC; Huang S; Jia Z; Zhang A Am J Physiol Renal Physiol; 2017 Apr; 312(4):F556-F564. PubMed ID: 28052869 [TBL] [Abstract][Full Text] [Related]
15. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease. Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Song W; Wei L; Du Y; Wang Y; Jiang S Int Immunopharmacol; 2018 Oct; 63():227-238. PubMed ID: 30107367 [TBL] [Abstract][Full Text] [Related]
17. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway. Lv C; Cheng T; Zhang B; Sun K; Lu K Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748 [No Abstract] [Full Text] [Related]
19. Astragaloside IV ameliorates diabetic nephropathy in Feng H; Zhu X; Tang Y; Fu S; Kong B; Liu X Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34278447 [TBL] [Abstract][Full Text] [Related]
20. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy. Xu X; Zhang L; Hua F; Zhang C; Zhang C; Mi X; Qin N; Wang J; Zhu A; Qin Z; Zhou F Exp Cell Res; 2021 Nov; 408(2):112863. PubMed ID: 34626587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]